Brooks Laboratories Share Price
Sector: Major Drugs
135.10 -1.85 (-1.35%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
135
Today’s High
138.75
52 Week Low
72.51
52 Week High
202.80
138.89 +1.20 (0.87%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
134
Today’s High
139.80
52 Week Low
73.25
52 Week High
198.86
Key Metrics
- Market Cap (In Cr) 397.97
- Beta 1.22
- Div. Yield (%) 0
- P/B 5.51
- TTM P/E -
- Peg Ratio -
- Sector P/E 0
- Open Price 138.75
- Prev Close 136.95
Brooks Laboratories Analysis
Price Analysis
-
1 Week5.13%
-
3 Months2.45%
-
6 Month1.24%
-
YTD-23.57%
-
1 Year48.85%
Risk Meter
- 59% Low risk
- 59% Moderate risk
- 59% Balanced Risk
- 59% High risk
- 59% Extreme risk
Brooks Laboratories News
Round tripping of funds: Sebi slaps Rs18 crore fine on 22 entities
2 min read . 17 Aug 2017Brooks Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 79.49
- Selling/ General/ Admin Expenses Total
- 15.97
- Depreciation/ Amortization
- 1.77
- Other Operating Expenses Total
- 1.23
- Total Operating Expense
- 78.04
- Operating Income
- 1.44
- Net Income Before Taxes
- -19.57
- Net Income
- -19.59
- Diluted Normalized EPS
- -7.65
- Period
- 2024
- Total Assets
- 90.45
- Total Liabilities
- 24.86
- Total Equity
- 65.59
- Tangible Book Valueper Share Common Eq
- 24.96
- Period
- 2024
- Cashfrom Operating Activities
- -9.68
- Cashfrom Investing Activities
- 0.18
- Cashfrom Financing Activities
- 9.6
- Net Changein Cash
- 0.1
- Period
- 2023
- Total Revenue
- 63.2
- Selling/ General/ Admin Expenses Total
- 28.35
- Depreciation/ Amortization
- 7.03
- Other Operating Expenses Total
- 4.22
- Total Operating Expense
- 96.25
- Operating Income
- -33.05
- Net Income Before Taxes
- -38.38
- Net Income
- -20.9
- Diluted Normalized EPS
- -8.47
- Period
- 2023
- Total Assets
- 109.6
- Total Liabilities
- 35.64
- Total Equity
- 73.95
- Tangible Book Valueper Share Common Eq
- 29.57
- Period
- 2023
- Cashfrom Operating Activities
- -14.49
- Cashfrom Investing Activities
- 0.49
- Cashfrom Financing Activities
- 11.41
- Net Changein Cash
- -2.58
- Period
- 2022
- Total Revenue
- 91.18
- Selling/ General/ Admin Expenses Total
- 33.11
- Depreciation/ Amortization
- 7.35
- Other Operating Expenses Total
- 1.49
- Total Operating Expense
- 112.56
- Operating Income
- -21.38
- Net Income Before Taxes
- -23.9
- Net Income
- -11.29
- Diluted Normalized EPS
- -4.56
- Period
- 2022
- Total Assets
- 195.91
- Total Liabilities
- 132.86
- Total Equity
- 63.05
- Tangible Book Valueper Share Common Eq
- 25.03
- Period
- 2022
- Cashfrom Operating Activities
- -37.44
- Cashfrom Investing Activities
- -24.91
- Cashfrom Financing Activities
- 64.07
- Net Changein Cash
- 1.72
- Period
- 2021
- Total Revenue
- 77.25
- Selling/ General/ Admin Expenses Total
- 14.37
- Depreciation/ Amortization
- 7.14
- Other Operating Expenses Total
- 14.73
- Total Operating Expense
- 83.81
- Operating Income
- -6.57
- Net Income Before Taxes
- -8.99
- Net Income
- -19.38
- Diluted Normalized EPS
- -7.75
- Period
- 2021
- Total Assets
- 162.08
- Total Liabilities
- 82.93
- Total Equity
- 79.15
- Tangible Book Valueper Share Common Eq
- 31.46
- Period
- 2021
- Cashfrom Operating Activities
- 4.46
- Cashfrom Investing Activities
- -5.13
- Cashfrom Financing Activities
- 1.16
- Net Changein Cash
- 0.49
- Period
- 2020
- Total Revenue
- 69.69
- Selling/ General/ Admin Expenses Total
- 13.38
- Depreciation/ Amortization
- 6.65
- Other Operating Expenses Total
- 12.05
- Total Operating Expense
- 78.9
- Operating Income
- -9.22
- Net Income Before Taxes
- -13.51
- Net Income
- -24.38
- Diluted Normalized EPS
- -6.75
- Period
- 2020
- Total Assets
- 157.86
- Total Liabilities
- 59.45
- Total Equity
- 98.42
- Tangible Book Valueper Share Common Eq
- 39.35
- Period
- 2020
- Cashfrom Operating Activities
- -9.39
- Cashfrom Investing Activities
- -2.33
- Cashfrom Financing Activities
- 9.61
- Net Changein Cash
- -2.1
- Period
- 2019
- Total Revenue
- 55.03
- Selling/ General/ Admin Expenses Total
- 12.16
- Depreciation/ Amortization
- 6.5
- Other Operating Expenses Total
- 11.79
- Total Operating Expense
- 69.89
- Operating Income
- -14.86
- Net Income Before Taxes
- -14.95
- Net Income
- -14.81
- Diluted Normalized EPS
- -7.62
- Period
- 2019
- Total Assets
- 167.88
- Total Liabilities
- 62.73
- Total Equity
- 105.15
- Tangible Book Valueper Share Common Eq
- 53.51
- Period
- 2019
- Cashfrom Operating Activities
- -5.05
- Cashfrom Investing Activities
- 1.12
- Cashfrom Financing Activities
- 5.78
- Net Changein Cash
- 1.85
- Period
- 2024-12-31
- Total Revenue
- 38.45
- Selling/ General/ Admin Expenses Total
- 6.37
- Depreciation/ Amortization
- 0.78
- Other Operating Expenses Total
- 5.16
- Total Operating Expense
- 37.38
- Operating Income
- 1.07
- Net Income Before Taxes
- -4.55
- Net Income
- -4.57
- Diluted Normalized EPS
- -1.75
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 20.79
- Selling/ General/ Admin Expenses Total
- 3.21
- Depreciation/ Amortization
- 0.43
- Other Operating Expenses Total
- 2.87
- Total Operating Expense
- 19.71
- Operating Income
- 1.08
- Net Income Before Taxes
- -3.96
- Net Income
- -3.96
- Diluted Normalized EPS
- -1.51
- Period
- 2024-09-30
- Total Assets
- 91.12
- Total Liabilities
- 31.92
- Total Equity
- 59.21
- Tangible Book Valueper Share Common Eq
- 22.55
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -0.99
- Cashfrom Investing Activities
- -0.5
- Cashfrom Financing Activities
- 1.54
- Net Changein Cash
- 0.04
- Period
- 2024-06-30
- Total Revenue
- 17.93
- Selling/ General/ Admin Expenses Total
- 3.07
- Depreciation/ Amortization
- 0.4
- Other Operating Expenses Total
- 2.27
- Total Operating Expense
- 18.05
- Operating Income
- -0.12
- Net Income Before Taxes
- -2.41
- Net Income
- -2.41
- Diluted Normalized EPS
- -0.92
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 17.72
- Selling/ General/ Admin Expenses Total
- 2.28
- Depreciation/ Amortization
- 0.46
- Other Operating Expenses Total
- 2.35
- Total Operating Expense
- 17.8
- Operating Income
- -0.08
- Net Income Before Taxes
- -9.61
- Net Income
- -9.61
- Diluted Normalized EPS
- -3.75
- Period
- 2024-03-31
- Total Assets
- 90.45
- Total Liabilities
- 24.86
- Total Equity
- 65.59
- Tangible Book Valueper Share Common Eq
- 24.96
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -9.68
- Cashfrom Investing Activities
- 0.18
- Cashfrom Financing Activities
- 9.6
- Net Changein Cash
- 0.1
- Period
- 2023-12-31
- Total Revenue
- 21.75
- Selling/ General/ Admin Expenses Total
- 2.84
- Depreciation/ Amortization
- 0.43
- Other Operating Expenses Total
- 2.35
- Total Operating Expense
- 21.09
- Operating Income
- 0.66
- Net Income Before Taxes
- -3.85
- Net Income
- -3.88
- Diluted Normalized EPS
- -1.51
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Brooks Laboratories Technical
Moving Average
SMA
- 5 Day134.97
- 10 Day133.13
- 20 Day135.37
- 50 Day123.11
- 100 Day141.42
- 300 Day136.94
Brooks Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Themis Medicare
- 169.8
- 20.4
- 13.65
- 313.65
- 115.05
- 1569.11
- Ind-swift Laboratories
- 72.33
- 1.03
- 1.44
- 186
- 67.15
- 440.76
- Brooks Laboratories
- 135.1
- -1.85
- -1.35
- 202.8
- 72.51
- 397.97
- Ambalal Sarabhai Enterprises
- 38.82
- -0.46
- -1.17
- 77.7
- 34.11
- 297.88
- Pharmaids Pharmaceuticals
- 67.94
- 1.07
- 1.6
- 87.46
- 31.9
- 239.6
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Themis Medicare
- 32.01
- 3.68
- 18.03
- 14.96
- Ind-swift Laboratories
- 3.02
- 0.45
- 13.45
- 8.52
- Brooks Laboratories
- -
- 5.51
- -21.61
- -27.47
- Ambalal Sarabhai Enterprises
- 53.12
- 2.2
- 23.77
- 12.86
- Pharmaids Pharmaceuticals
- -
- 3.27
- -17.27
- -69.29
Brooks Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Feb-25
- Quarterly Results
- 11-Dec-24
- To consider Fund Raising & Others
- 09-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 18-May-24
- Audited Results
- 31-Jan-24
- Quarterly Results
- 24-Jan-24
- Rights & Preferential issue
- 09-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 18-Jul-23
- Rights issue of Equity Shares
- Meeting Date
- Announced on
- Purpose
- 11-Jan-25
- 19-Dec-24
- EGM
- 19-Sept-24
- 02-Sept-24
- AGM
- 21-Sept-23
- 01-Sept-23
- AGM
- 05-Mar-23
- 31-Jan-23
- POM
- 29-Sept-22
- 03-Sept-22
- AGM



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 25-Jan-23
- 28-Jul-23
- 28-Jul-23
- 1:16
- 10
- 65
- Rights issue of equity shares of Rs. 10/- in the ratio of 1:16 @ premium of Rs. 65/-.